The drug sofosbuvir has been available since January 2014 as a treatment for chronic hepatitis C infection. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the ...
May 2, 2014
0
0
Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials ...
Apr 12, 2014
0
1
Data from a late-breaking abstract presented at the International Liver Congress 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' ...
Apr 12, 2014
0
0
Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ...
Apr 12, 2014
0
0
Researchers at the Sahlgrenska Academy, University of Gothenburg, have identified a gene, which explains why certain patients with chronic hepatitis C do not experience relapse after treatment. The discovery may contribute ...
Mar 13, 2014
0
0
(HealthDay)—The prevalence of hepatitis C virus (HCV) infection is about 1 percent, with 2.7 million U.S. residents estimated as having chronic HCV infection, according to a study published in the March 4 issue of the Annals ...
Mar 4, 2014
0
0
Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 ...
Feb 19, 2014
0
0
The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected. The ...
Jan 14, 2014
0
0
The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede ...
Dec 9, 2013
0
0
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug for chronic hepatitis C infection that some experts hope will cut down on side effects from current therapies.
Nov 25, 2013
0
0
